PMID- 32774321
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1664-2295 (Print)
IS  - 1664-2295 (Electronic)
IS  - 1664-2295 (Linking)
VI  - 11
DP  - 2020
TI  - Correlation Between Thioredoxin-Interacting Protein and Nerve Conduction Velocity 
      in Patients With Type 2 Diabetes Mellitus.
PG  - 733
LID - 10.3389/fneur.2020.00733 [doi]
LID - 733
AB  - Aims: To investigate the correlation between thioredoxin-interacting protein 
      (TXNIP) and peripheral nerve conduction velocity (NCV) in patients with type 2 
      diabetes mellitus. Methods: In total, 338 patients with type 2 diabetes mellitus 
      (T2DM) were included in this study. We collected the clinical data and measured 
      the motor conduction velocities of the bilateral ulnar nerve, median nerve, 
      tibial nerve, and common peroneal nerve, and the sensory conduction velocities of 
      the ulnar nerve, median nerve, sural nerve, and superficial peroneal nerve. 
      According to the results, the patients were divided into two groups: normal 
      peripheral nerve conduction group (NCVN group) and abnormal peripheral nerve 
      conduction group (NCVA group). The two groups were then compared in terms of the 
      conventional biochemical index and the sugar metabolic index as well as the serum 
      levels of TXNIP, reduced glutathione (GSH), total superoxide dismutase (SOD), 
      malondialdehyde (MDA), and tumor necrosis factor alpha (TNF-alpha). The correlation 
      between TXNIP and NCV was also analyzed. Results: Compared with the NCVN group, 
      the TXNIP and MDA values were significantly increased in the NCVA group (P < 
      0.05). Among the patients with T2DM, age, fasting glucose, SDBG, and TXNIP were 
      risk factors for NCV abnormality, while vitamin D3 was a protective factor. After 
      adjusting for related confounding factors, TXNIP was significantly correlated 
      with NCV (P < 0.05). Among the patients with T2DM, TXNIP was an independent risk 
      factor for left ulnar motor conduction velocity (MCV), right ulnar MCV, left 
      median MCV, and right median MCV. TNF-alpha was identified as a positive influencing 
      factor for serum TXNIP, while serum TXNIP was a positive factor for TNF-alpha and MDA 
      (both P < 0.05). Conclusion: Serum TXNIP is related to NCV in T2DM patients. In 
      combination with oxidative stress and inflammation, TXNIP may affect diabetic 
      peripheral neuropathy (DPN).
CI  - Copyright (c) 2020 Gao, Chen, Peng, Wang, Ren, Mu and Zheng.
FAU - Gao, Yuan
AU  - Gao Y
AD  - Department of Endocrinology, Hebei General Hospital, Shijiazhuang, China.
AD  - Graduate School of North China University of Science and Technology, Tangshan, 
      China.
FAU - Chen, Shuchun
AU  - Chen S
AD  - Department of Endocrinology, Hebei General Hospital, Shijiazhuang, China.
FAU - Peng, Minmin
AU  - Peng M
AD  - Department of Endocrinology, Hebei General Hospital, Shijiazhuang, China.
AD  - Graduate School of Hebei North University, Zhangjiakou, China.
FAU - Wang, Zi
AU  - Wang Z
AD  - Department of Endocrinology, Hebei General Hospital, Shijiazhuang, China.
AD  - Graduate School of Hebei North University, Zhangjiakou, China.
FAU - Ren, Luping
AU  - Ren L
AD  - Department of Endocrinology, Hebei General Hospital, Shijiazhuang, China.
FAU - Mu, Shumin
AU  - Mu S
AD  - Department of Endocrinology, Hebei General Hospital, Shijiazhuang, China.
AD  - Graduate School of North China University of Science and Technology, Tangshan, 
      China.
FAU - Zheng, Meiling
AU  - Zheng M
AD  - Department of Endocrinology, Hebei General Hospital, Shijiazhuang, China.
AD  - Graduate School of Hebei Medical University, Shijiazhuang, China.
LA  - eng
PT  - Journal Article
DEP - 20200722
PL  - Switzerland
TA  - Front Neurol
JT  - Frontiers in neurology
JID - 101546899
PMC - PMC7387714
OTO - NOTNLM
OT  - TXNIP
OT  - oxidative stress
OT  - peripheral nerve conduction velocity
OT  - tumor necrosis factor alpha
OT  - type 2 diabetes mellitus
EDAT- 2020/08/11 06:00
MHDA- 2020/08/11 06:01
PMCR- 2020/07/22
CRDT- 2020/08/11 06:00
PHST- 2020/03/07 00:00 [received]
PHST- 2020/06/15 00:00 [accepted]
PHST- 2020/08/11 06:00 [entrez]
PHST- 2020/08/11 06:00 [pubmed]
PHST- 2020/08/11 06:01 [medline]
PHST- 2020/07/22 00:00 [pmc-release]
AID - 10.3389/fneur.2020.00733 [doi]
PST - epublish
SO  - Front Neurol. 2020 Jul 22;11:733. doi: 10.3389/fneur.2020.00733. eCollection 
      2020.